Last updated on April 2019

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone


Brief description of study

This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.

Detailed Study Description

This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed by sorafenib versus sorafenib in patients with advanced HCC without prior systemic therapy.

A total of 600 patients will be randomly assigned to 2 treatment arms in a 1:1 ratio (300 in each arm) to reach at least 570 evaluable patients.

Clinical Study Identifier: NCT02562755

Contact Investigators or Research Sites near you

Start Over

Site No. 8414

Heidelberg, Australia
3.44miles
  Connect »

Site No. 8408

Fitzroy, Australia
4.32miles
  Connect »

Site No. 8402

Parkville, Australia
4.4miles
  Connect »

Site No. 8411

Melbourne, Australia
5.46miles
  Connect »

Site No. 8405

Footscray, Australia
7.06miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.